M A N U S C R I P T Introduction
Cystic fibrosis (CF) patients are regularly colonized by opportunistic microorganisms. In adult patients, Pseudomonas aeruginosa is the main pathogen, but in recent years, other nonfermenting bacteria from different genera, such as Stenotrophomonas, Burkholderia, Achromobacter, Ralstonia, and Pandoraea, are increasingly being isolated [1] [2] [3] . This could be potentially due to the aggressive antimicrobial therapy used against P. aeruginosa, to the apparition of new techniques for the bacterial identification and improvement in life expectancy for people with CF [4] .
In most cases, it has been reported that chronic colonization with these microorganisms is associated with a decline in pulmonary function; however, the pathogenic role of some of these species is not completely clear due to their coexistence with other pathogens including Staphylococcus aureus and P. aeruginosa [4] . Unlike P. aeruginosa, for which antimicrobial treatment is standardized, treatment protocols are not in place for these non-fermenting microorganisms and limited data is available regarding their susceptibility profiles. Studying the susceptibility patterns and the epidemiology of these microorganisms is essential to improve the management of CF patients.
The aim of this study was to determine the susceptibility of CF non-fermenting Gramnegative bacteria other than P. aeruginosa to a range of antimicrobials used in CF patients. This study is included within the objectives of the IMI-iABC European project which is mainly focused on the development of a new inhaled compound for CF patients. Achromobacter sp., 2 A. insolitus), 12 Pandoraea spp. and 9 Ralstonia spp. isolates were studied. These bacteria were identified by MALDI-TOF MS; the identification was confirmed by whole genome sequencing. The species of Burkholderia were also confirmed by sequencing the recA gene as previously described [5] .
Material and Methods
MIC's were determined by standard ISO broth microdilution method with frozen panels (Trek Diagnostic Systems, Westlake, Ohio). The antibiotics and its concentration range tested (Table   1 , Table 2 , Figure 1 ). To analyze the data by country, chi-square/Fisher test with the Bonferroni correction was used in order to compare susceptibility rates when an antibiotic breakpoint was available (statistically significant when P<0.016). To reflect differences in mechanisms of antibiotic resistance between countries, MIC 90 values were graphically represented ( Figure S1 ).
Statistical analysis was performed using STATA statistical software for Windows (Data Analysis and Statistical Software, version 11.0). Isolates categorized as intermediate and susceptible were grouped for data analysis.
Results
MIC 50 and MIC 90 results for all the tested antibiotics and microorganisms are presented in Table   1 . SXT was the most active compound for all the microorganisms, with a MIC 50 range of 0.12-4 mg/L, and a MIC 90 range of 1-16 mg/L. All the microorganisms presented either a COL MIC 50 or MIC 90 higher than 16 mg/L. Analysing S. maltophilia isolates, 47% and 62% of the isolates were susceptible to SXT when considering CLSI (S≤2, R≥4 mg/L) and EUCAST (S≤4, R>4 mg/L) clinical breakpoints, respectively (Table 2, Figure 1 ). Coinciding with CLSI breakpoint, the EUCAST SXT ECOFF is 2 mg/L, which means that 47% of the isolates were included in the wild-type population.
CAZ presented a lower level of susceptibility (S 35%; I 6%; R 59%), placing both, the MIC 50 (32 mg/L) and MIC 90 (256 mg/L) within the resistant population (Table 2, Figure 1 ). There are not defined clinical breakpoints for CIP, but the MIC 50 value (4 mg/L) was close to the EUCAST modal value (2 mg/L) in S. maltophilia. For both tobramycin and colistin, MIC 90 values were high (>128 mg/L, >16 mg/L, respectively).
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Considering all the Burkholderia species, according to CLSI breakpoints, 72%, 56% and 44% of the isolates were susceptible to SXT (S≤2, R≥4 mg/L), CAZ (S≤8 mg/L, I=16 mg/L, R≥32 mg/L) and MER (S≤4 mg/L, I=8 mg/L, R≥16mg/L), respectively ( Table 2) For S. maltophilia, there were no statistically significant differences between countries in CAZ and SXT susceptibility (p>0.016) as shown in Figure S1 , where the antibiotic MIC 90 values are reported for the separate countries.
Considering the origin of Burkholderia species, B. multivorans was most frequently isolated species in Northern Ireland and The Netherlands (48.6% and 68.6%, respectively) while in Spain it was B. contaminans (39.3%). A lower rate of MER susceptibility was observed for

A C C E P T E D M A N U S C R I P T
and The Netherlands (74.3%) although it was not statistically significant (p=0.02). Curiously similar MER MIC 90 values were observed between these countries (4-8 mg/L) ( Figure S1 ).
There were no statistically significant differences in CAZ and SXT susceptibility by country, although CAZ MIC 90 for isolates from Spain was 2-3 dilutions lower than the CAZ MIC 90 found in The Netherlands and Northern Ireland. The SXT MIC 90 for isolates from Northern Ireland was 2-3 dilutions lower than that found from Spain and The Netherlands.
For Achromobacter spp., SXT MIC 90 value reported from Northern Ireland was 4 dilutions lower than that from Spain.
Discussion
Non-fermentative Gram-negative bacteria other than P. aeruginosa, such as Burkholderia cepacia complex, Stenotrophomonas, Achromobacter, Ralstonia, and Pandoraea, are increasingly isolated in respiratory samples from CF patients. These microorganisms are in general intrinsically resistant to multiple antibiotics and treatment guidelines are not yet available, so clinicians judge each patient individually considering the in vitro antimicrobial susceptibility reports and clinical outcome after therapy. Furthermore, the available clinical breakpoints are intended for systemic therapy and may not be adequate for inhaled therapy.
Inhaled therapy has the potential to achieve high pulmonary concentrations and may be able to inhibit microorganisms with MICs above the breakpoints for systemic therapy [6] .
Some studies have defined S. maltophilia as a colonizer, while others demonstrated that this microorganism is capable of causing a deterioration in pulmonary function [7, 8] .
Nevertheless, the presence of S. maltophilia cannot be ignored in some patients, as it is associated with an increased risk of pulmonary exacerbations, the need for lung transplantation, and death [9] . Generally, SXT is the antibiotic of choice, but during the last years increasing resistance rates are being reported in CF patients ranging from 16% to 45% [2, 3, 10, 11] . In our
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8 study, the SXT resistance rate was 38% and 53% following EUCAST and CLSI guidelines, respectively. Comparison between EUCAST MIC distribution and that obtained in this study shows a clear displacement of the latter to higher concentrations. In fact, the majority of non-CF S. maltophilia isolates are susceptible to SXT (global rate of less than 10% resistance) [12] .
Although CAZ and fluoroquinolones are considered as options for S. maltophilia, high resistance rates of both compounds are also increasingly being reported. In our study, approximately 60% of the isolates were CAZ resistant, a rate similar to that previously published (80% [13] , 70% [2] ). Newer fluoroquinolones, such as moxifloxacin may have a better activity against S. maltophilia than CIP (MIC 90 = 32 mg/L in this study) [12] .
The isolation of Burkholderia spp. is particularly worrying in CF patients, as it is related to a rapid decline in pulmonary function and to a high morbidity and mortality [14] . Similar to S. maltophilia, SXT is the antibiotic of choice for Burkholderia spp., but combinations are frequently used. A lower SXT resistance rate (28%) was observed than for S. maltophilia.
Resistance rates for MER and CAZ were more than 30% for both antibiotics.
The clinical relevance of the isolation of species of Achromobacter in the sputum of CF patients is unclear. Some studies have demonstrated that its presence is associated with a risk of pulmonary exacerbation but not with a worsened long-term prognosis [15] . Also, Achromobacter isolated from people with CF seem to be more virulent than those isolated from other sources [16] . The most active agents for Achromobacter were SXT and IMI. In contrast to previously published data, MER was less active than IMI [16] . CAZ, COL, and TOB have been considered adequate for inhalation therapy [17] ; however, in this study, these antibiotics presented high MIC 90 values.
The prevalence of Ralstonia and Pandoraea infection in CF is low. The pathogenic role of Pandoraea spp. appears to be due to the increase in the production of pro-inflammatory cytokines, but the clinical impact is still uncertain [18] . Although only a limited number of Ralstonia and Pandoraea isolates were tested, our results demonstrated that IMI and SXT had
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As the scope of the initial research of the iABC project was to analyze P. aeruginosa susceptibility, a limitation of our study is that some antibiotics suitable for non-fermenters other than P. aeruginosa were not included in the MIC panels. However, the findings of our study provide insights about the epidemiology and susceptible patterns of these microorganisms from different geographical regions.
In conclusion, non-fermenting Gram-negative bacteria other than P. aeruginosa are potential pathogens increasingly being isolated from respiratory samples of CF patients. Little is known about their epidemiology, clinical management and antimicrobial susceptibility. We provide susceptibility testing data to different antimicrobials to better define their antimicrobial susceptibility profile. Considering available clinical breakpoints, SXT has demonstrated to be the most active compound against all isolates tested. 
